Dr. Michael Lowe
Surgical Oncology (Surgical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Georgetown University School of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 190
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Georgetown University School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Surgical Oncology Physician primary
GA license 065584 · NY license 273537
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Emory University Hospital Atlanta, GA
- Emory University Hospital Midtown Atlanta, GA
- Saint Joseph's Hospital of Atlanta, Inc Atlanta, GA
- Hillcrest Medical Center Tulsa, OK
Medical groups
- The Emory Clinic Inc (3,568 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 190
- Services billed
- 605
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 117 | 94 |
| New patient office or other outpatient visit, 45-59 minutes | 55 | 55 |
| Established patient office or other outpatient visit, 30-39 minutes | 39 | 34 |
| Imaging of lymph nodes during surgery | 37 | 37 |
| Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | 24 | 24 |
| Complicated repair of wound of scalp, arms, or legs, each additional 5.0 cm or less | 22 | 16 |
| Biopsy or removal of deep lymph nodes of underarm | 21 | 21 |
| Biopsy or removal of lymph nodes | 18 | 18 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 18 | 18 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 3 payments worth $5,116 in total to this clinician.
| Regeneron Pharmaceuticals, Inc. | $5,116 |
|---|
| Consulting Fee | $5,000 |
|---|---|
| Food and Beverage | $116 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. Jan 10, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $3,000 |
| Regeneron Pharmaceuticals, Inc. Jan 10, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $2,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $233,580 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab andNivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma [RELAtivity-098]
E.r. Squibb & Sons, L.l.c. - A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06190951 - Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716
Merck Sharp & Dohme LLC - Neadjuvant/adjuvant cemiplimab for high risk cutaneous squamous cell carcinoma
Regeneron Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.